Skip to main content
    S

    SeaStar Medical Holding Corporation (ICU)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.85
    +0.02 (+1.80%)

    Market Cap: $4.46M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    SeaStar Medical Holding Corporation (ICU) Earnings: Report Dates and Results

    Updated Nov 11, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    SeaStar Medical Holding (ICU) is expected to report earnings on Mar 23, 2027. In the quarter ended Sep 30, 2026, SeaStar Medical Holding reported EPS of -$1.03, below the -$0.95 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    40%(6/15)
    Avg Surprise
    -34.96%

    Upcoming Estimates

    Reports Mar 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.90
    RangeN/A
    3 analysts
    Revenue Consensus
    $443.39K
    Range$370.44K - $525.00K
    3 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.89
    Range-$0.89 - -$0.89
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.890.0%
    60d ago-$0.890.0%
    30d ago-$0.890.0%
    7d ago-$0.890.0%
    Current-$0.89
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    ICU has an expected report date of Mar 23, 2027.

    ICU Earnings Call

    The latest ICU earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 15 quarters below that had an estimate, ICU beat 6, missed 7 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $635000, up 247.0% from $183000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.03-$0.95-$0.95 - -$0.95-8.42%MissN/A10 up, 2 downNov 11, 2026$635000
    Jun 30, 2026-$0.91-$0.91-$1.03 - -$0.910.00%In lineN/A20 up, 2 downAug 12, 2026$615000
    Mar 31, 2026-$0.90-$0.82-$0.92 - -$0.73-9.76%MissN/A21 up, 0 downMay 13, 2026$495000
    Dec 31, 2025-$0.80-$1.02-$1.06 - -$0.97+21.18%BeatN/A21 up, 0 downMar 25, 2026$420000
    Sep 30, 2025-$1.30-$1.50-$1.50 - -$1.50+13.33%BeatN/A11 up, 0 downNov 13, 2025$183000
    Jun 30, 2025-$1.80-$4.30-$4.30 - -$4.30+58.14%BeatN/A10 up, 1 downAug 13, 2025$338000
    Mar 31, 2025-$4.40-$5.20N/A+15.38%BeatN/AN/A0 up, 0 downMay 14, 2025$293000
    Dec 31, 2024-$0.90-$0.18N/A-400.00%MissN/AN/A0 up, 0 downMar 27, 2025$67000
    Sep 30, 2024-$11.00-$11.30-$11.30 - -$11.30+2.65%BeatN/A10 up, 0 downNov 13, 2024$68000
    Jun 30, 2024-$10.30-$14.10-$14.10 - -$14.10+26.95%BeatN/A11 up, 0 downAug 13, 2024N/A
    Mar 31, 2024-$47.50-$37.50-$37.50 - -$37.50-26.67%MissN/A10 up, 0 downMay 14, 2024N/A
    Dec 31, 2023-$0.22-$0.13-$0.13 - -$0.13-69.23%MissN/A10 up, 0 downMar 13, 2024N/A
    Sep 30, 2023-$92.50-$62.50-$62.50 - -$62.50-48.00%MissN/A10 up, 0 downNov 14, 2023N/A
    Jun 30, 2023-$62.50-$62.50-$62.50 - -$62.500.00%In line-446528.6%10 up, 0 downAug 14, 2023N/A
    Mar 31, 2023-$100.00-$50.00N/A-100.00%Miss-1000100.0%N/AN/AMay 15, 2023N/A
    Dec 31, 2022-$2.04N/AN/AN/AN/A-192.3%N/AN/AMar 30, 2023N/A
    Sep 30, 2022-$0.05N/AN/AN/AN/A-350.0%N/AN/ANov 14, 2022N/A
    Jun 30, 2022$0.01N/AN/AN/AN/AN/AN/AN/AAug 16, 2022N/A
    Mar 31, 2022$0.01N/AN/AN/AN/A-94.4%N/AN/AApr 6, 2022N/A
    Dec 31, 2021$2.22N/AN/AN/AN/AN/AN/AN/AMar 31, 2022N/A
    Sep 30, 2021$0.02N/AN/AN/AN/AN/AN/AN/ANov 17, 2021N/A
    Jun 30, 2021-$0.15N/AN/AN/AN/AN/AN/AN/AAug 16, 2021N/A
    Mar 31, 2021$0.18N/AN/AN/AN/AN/AN/AN/AMay 24, 2021N/A
    Last 23 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$8.30, after -$69.70 the year before. It was $2.27 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$8.30N/A
    Dec 31, 2024-$69.70N/A
    Dec 31, 2023-$255.22N/A
    Dec 31, 2022-$2.07-191.4%
    Dec 31, 2021$2.27N/A

    Earnings Calls

    The 5 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,800 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,8068
    2026Q2Jun 30, 20263,8128
    2026Q1Mar 31, 20264,2208
    2025Q3Sep 30, 20254,3477
    2025Q1Mar 31, 20253,9657

    2026Q3 Earnings Call

    Opening remarks

    Jackie Cossmon Conference Call Host Thank you, Latif. Good afternoon, and thank you for joining the SeaStar Medical Third Quarter 2026 Financial Results Conference Call. I'm Jackie Cossmon with Wheelhouse Life Science Advisors. Joining me from SeaStar Medical today are Eric Schlorff, Chief Executive Officer; Tim Varacek, Senior Vice President of Commercial and Business Operations; Dr. Kevin Chung, Chief Medical Officer; and Mike Messinger, Chief Financial Officer. I would like to remind listeners that comments made during this call by management will include forward-looking statements within the meaning of federal securities laws. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any anticipated results. For a list and description of these risks and uncertainties, please review SeaStar Medical's filings with the Securities and Exchange Commission. Furthermore, the content of this conference call contains information that is accurate only as of the date of the live broadcast, November 11, 2026. SeaStar Medical undertakes no obligation to revise or update any statements to reflect events or circumstances, except as required by law. And now I'll turn the call over to Eric. Eric?

    Eric Schlorff CEO Thank you, Jackie, and thank you all for joining us today. We made good progress on several fronts this quarter. We saw strong QUELIMMUNE demand in the ultra-rare pediatric AKI market, and we continue to build momentum in educating the critical care pediatric health care community. Kevin Chung, our CMO, presented data on QUELIMMUNE at several medical meetings, and we are already sharing with critical care professionals the statistically significant higher survival in QUELIMMUNE-treated patients in our patient registry that was highlighted at the late-breaking presentation at ASN Kidney Week 2026. Importantly, we believe this growing momentum of interest reinforces the promise of our SCD therapy for our pipeline indications, the first of which is for adult patients with AKI on continuous renal replacement therapy, or CRRT. The NEUTRALIZE-AKI pivotal clinical trial for this patient population is well underway and has enrolled about 75% of its intended 339 patients. The results of this trial will be critical for understanding the role of our SCD therapy in preventing lifelong dialysis treatment and saving lives. As we have said previously, our enrollment in this trial is moderated by strict inclusion and exclusion criteria designed to enroll patients most appropriate for the study, which supports a well-defined trial population and more rigorous evaluation of the SCD's potential benefit in these patients. As a result, we are adjusting our guidance for completion of enrollment in the trial. Based on our current enrollment rate, we would anticipate completing the trial by midyear of 2027.

    Frequently Asked Questions About ICU

    When is SeaStar Medical Holding's next earnings date?

    SeaStar Medical Holding's next earnings report is expected for Mar 23, 2027.

    Did ICU beat earnings estimates last quarter?

    No. SeaStar Medical Holding reported EPS of -$1.03 for the quarter ended Sep 30, 2026, below the -$0.95 estimate by 8.42%.

    What EPS do analysts expect from ICU next quarter?

    The consensus EPS estimate for SeaStar Medical Holding for the quarter ending Dec 31, 2026 is -$0.90 from 3 analysts.

    How often does ICU beat earnings estimates?

    SeaStar Medical Holding beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -38.77%.